Prime Medicine Stock News

Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson's Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 mil...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeuti...

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:

These 12 innovative companies could deliver exponential returns over the next quarter century.

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies

This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.

-- On-track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from a...

You've likely heard that penny stocks are high-risk investments, and if so, you've heard right.